PPT-A Fabry terápia fejlődése

A raremark 2017 július 7én megjelent Fabry disease treatment and management cikke alapján httpsraremarkcomfabrydiseasearticlesfabrydiseasetreatmentandmanagement579. The cytoskeleton as a soft glassy material (Fredberg & Fabry) twisting field displacementcell rotation Fig. 1a (from (Fabry, Maksym et al., 2003)): Scanning EM of a bead b . Spectrographs. Measurements . of the line shift.. a(. sin. a. sin. b. ). g. rating constant. Echelle. spectrometer. The first . standard grating . is optimized for a single lower . order. The . echelle. EN PACIENTES . VIH ( ). Q.F. Beatriz Soledad Bustamante Gómez. Encargada de Farmacia de Atención Abierta y Programa Ministerial VIH/SIDA. Mayo, 2016. INTRODUCCIÓN. Introducción. INICIO. 35 años desde el inicio de TARV.. Tartalom. Jelképrendszer . és a . képírásjelek. . Mítosz . – Monda – Szimbólum - Embléma. A . misztériumnyelv . kulcsa. . A . hét . kulcs. A . héberek geometriai . Atua principalmente nas seguintes áreas: voz, linguagem oral e escrita, teatro e . canto.. FORMAÇÃO . profissional. Fonoaudióloga. , USP - 1979. Mestre em Distúrbios da Comunicação, . PUC-SP . 5 anni fa IMA trattato con 3 . stents. . e attualmente in terapia con nitroderivati , . cardioaspirina. , antipertensivi (antagonisti dell’. angiotensina. II) e statine. Da due mesi accusa episodi di dolore . Dr. Michael L. West. Division of Nephrology. Department of Medicine. Dalhousie University. Halifax NS. Canada. mlwest@dal.ca. Fabry Disease. . OMIM #301500. Glycosphingolipid= Gb3. Most specific therapies in Fabry disease increase . Storage Diseases. Michael . H. Gelb (. Dept. . of . Chemistry & Biochemistry, . Univ. of Washington. ). 30 . yrs. of experience in enzymology, organic chemistry, mass spec.. Frank . Turecek. (Dept. of Chemistry, Univ. of Washington. Pierandrea De Iaco. Oncologia Ginecologica. Policlinico . S.Orsola. – Malpighi. Bologna. La . chirurgia. . fertility sparing . permette. di . conservare. . l’utero. e . tessuto. . ovarico. per . IntroductionFabry disease (FD) arises from an X-linked defect in lipid storage, whereby deicient or -galactosidase A (-gal A) activity leads to systemic deposition of glyco-sphingolipids, mainly Page 64 of 69 FMNry diseMse: ProPoPype of IysosomMl SPorMge Gisorder RiPO sysPemic Hrene SMn-Román-MonserrMP*, JuMn-RMmón Gimeno-BlMnes Article InfoArticle Notes Fabry disease is a rare inherited m • What is Fabry Disease?• What Causes Fabry?• How Common is Fabry? Guide to Understanding Fabry Disease mps@mpssociety.or.ukwww.mpssociety.or.uk Dianosis of Fabry DiseaseFabry Dis Special thanks toShireThe full article and its related educational materialwere produced by and under the sole responsibility of the Working Group on Myocardial and Pericardial Diseases. ESC WORKING G Supported by Sanofi Genzyme. Agenda. Pathogenesis of . Fabry. Disease. Evaluation of . Fabry. Disease. Fabry. Disease Management. Learning Objectives. Discuss the pathophysiology of . Fabry. disease and its impact on kidney function to increase awareness.